Infinite Intelligence Pharma Secures Pre-A Investment from Livzon Pharmaceutical to Advance AI-Powered Drug Discovery Platform

VCBeat (WeChat ID: vcbeat) has exclusively learned that on February 5, 2021, Beijing Inflygent Pharmaceutical AI Technology Co., Ltd. (Inflygent Pharmaceutical AI) announced it had secured Pre-A round investment from Zhuhai Livzon Pharmaceutical Equity Investment Management Co., Ltd., the wholly-owned investment platform of Livzon Pharmaceutical Group Inc. (1513.HK, 000513.SZ).

According to Inflygent Pharmaceutical AI, with the support of angel investment from CAS Star and United Group obtained in August 2019, its AI-driven new drug development platform, “InflyBrain,” has taken shape. The platform integrates cutting-edge Artificial Intelligence Drug Design (AIDD) and next-generation Computer-Aided Drug Design (CADD) technologies, providing comprehensive coverage of the entire process from target discovery to preclinical candidate compounds. “InflyBrain” performs precise computational predictions of the multidimensional properties of designed compounds, significantly enhancing the level of innovative drug R&D and early-stage success rates at the source, thereby meeting the pharmaceutical industry’s urgent need for improved efficiency and accelerated development.

Dr. Jianfeng Pei, Founder of Inflygent Pharmaceutical AIstated: "The third wave of artificial intelligence development is currently in full swing, significantly transforming human lifestyles and the paradigm of scientific and technological R&D, with breakthroughs in new drug discovery expected in the near future. Inflygent Pharmaceutical AI is committed to advancing efficient and powerful AI-driven new drug discovery technologies and platforms, with a mission to reduce the overall average cost of new drug development in the global pharmaceutical industry to less than one-tenth of its current level. This financing round will be used to upgrade the team, enhance the intelligent drug discovery system, and expand the R&D pipeline, thereby better serving global pharmaceutical companies, biotechnology firms, and partners. Inflygent Pharmaceutical AI also aims to leverage this financing to achieve world-class, point-specific breakthroughs in AI-driven new drug discovery technologies and its drug development pipeline."

Dr. Liu Jianing, Chief Investment Officer of Livzon Pharmaceutical Group“The global pharmaceutical industry is in urgent need of AI-driven drug discovery companies that can truly understand the demands of drug R&D and design innovative pharmaceutical molecules with clinical advantages. We highly recognize the technical capabilities and R&D direction of Inflygent Pharmaceutical AI’s AI-powered drug discovery platform. In its early startup phase, Inflygent has demonstrated a profound understanding of how AI can practically and effectively empower new drug development, along with strong execution capabilities. Its developed R&D module system and algorithms are at a leading level internationally. Livzon Pharmaceutical Group is honored to have found such a long-term partner to jointly address the challenges and pain points in new drug development.”

Inflygent Pharmaceutical AI has assembled a team of top-tier domestic experts in drug design and AI-driven drug discovery, pioneering the application of cutting-edge AI technologies to new drug development both internationally and as the first in China. Over the past year and a half, Inflygent Pharmaceutical AI has leveraged its accumulated technical expertise and successful experience to develop PharmaMind, an AI-powered new drug discovery system with independent intellectual property rights.

Driven by data, expertise, and technology, the Intelligent Drug Discovery Brain integrates expert intelligence, computational intelligence, perceptual intelligence, and cognitive intelligence. Tailored to real-world scenarios in new drug development, this system develops and consolidates multiple foundational drug discovery tools, enabling workflow adaptation based on actual business needs. The Intelligent Drug Discovery Brain platform features a suite of globally leading, practical core technologies, including “system-based target discovery and combination analysis,” “prediction of potential drug-resistance mutation sites in drug targets,” “structure-based protein druggability analysis,” “structure-based 3D molecular generation,” “high-precision ultra-high-throughput virtual screening,” “optimization of lead compounds with high developability,” “de novo design and optimization for multi-target drugs,” “allosteric drug/IDP drug design,” and “high-precision compound structure image recognition.” Addressing unmet clinical needs, Inflygent Pharmaceutical AI leverages the Intelligent Drug Discovery Brain system to advance new drug development pipelines that demonstrate the absolute advantages of AI technology. Currently, these pipelines are progressing smoothly and have yielded encouraging results.

Livzon Pharmaceutical Group Inc. (1513.HK, 000513.SZ) is a leading comprehensive pharmaceutical group in China, integrating research and development, manufacturing, and sales. Zhuhai Livzon Pharmaceutical Equity Investment Management Co., Ltd. is a wholly-owned investment platform established by Livzon Pharmaceutical in Hengqin, Zhuhai, dedicated to identifying and supporting leading innovative pharmaceutical technologies and product development in China.

Oriented toward investing in "hard technology," CAS Star established its healthcare investment team in 2017, primarily focusing on upstream and midstream R&D and manufacturing enterprises within the pharmaceutical and medical device industry chains. To date, it has participated in investments in more than 20 early-stage companies. Its investment portfolio includes Kekai Life, Bodong Medical, Wushuang Medical, CAS Micro-Light, Chuanshi Biology, Shenxin Biology, Zehui Biology, and Lianxin Medical. CAS Star’s healthcare investment arm has actively explored the commercialization of scientific research achievements from universities and research institutions; among its portfolio companies, more than ten were incubated by institutions such as the Chinese Academy of Sciences, Peking University, Tsinghua University, Westlake University, and Shanghai Jiao Tong University.

United Venture Capital Group, established in 1993, is the first global cross-border venture capital firm to enter the Asia-Pacific region. It focuses on investing in cutting-edge innovative technology projects worldwide, actively promoting technological advancement and the societal application of scientific achievements, thereby continuously creating value for society. The group maintains a sustained focus on three key investment sectors: healthcare, enterprise intelligence, and sustainable development. With offices currently located in Silicon Valley, Beijing, and Taipei, it has invested in over 400 companies and achieved more than 100 successful exits through initial public offerings (IPOs) and mergers and acquisitions (M&A).

In the healthcare sector, we focus on innovative biopharmaceuticals, digital health, medical devices, and healthcare services. We have invested in companies such as iKang Healthcare Group, Medicalsystem Technology, Edan Instruments, and LabTech, all of which are publicly listed. Furthermore, we have strategically invested in dozens of outstanding startups, including BoYa Gene Editing, SYNTHEGO, KingMed Diagnostics, Panorama Medicine, Inflygent Pharmaceutical AI, Engine Biosciences, DeepBiome, CareRay, Rongxin Medical, Hengdao Pathology, NeuroXess, AnZhi Biomedical, and Kemei Diagnostics.